Evoke Pharma to Showcase Award-Winning Research at ACG 2024
Evoke Pharma, Inc. (NASDAQ: EVOK), based in Solana Beach, California, is making headlines once again in the field of gastrointestinal (GI) treatments. The company is set to present its innovative research at the upcoming American College of Gastroenterology (ACG) Annual Scientific Meeting.
Recognizing Excellence in GI Research
At this important event, which will occur over several days in Philadelphia, Evoke Pharma is excited to feature two poster presentations that delve into the applications of its GIMOTI (metoclopramide) nasal spray. Among these, one significant abstract, numbered P3339, has been awarded the prestigious Outstanding Research Award in the Stomach Category by ACG, honoring it as the top research in this segment. Additionally, this abstract has received the Presidential Poster Award, a distinction given to fewer than 5% of submissions, showcasing groundbreaking and impactful research.
Details of Poster Presentations
Here are some details regarding the poster presentations at the ACG meeting:
- Poster Number: P1606
- Session Time: Sunday, October 27, 3:30 p.m. – 7:00 p.m. ET
- Presenting Authors: Richard McCallum, MD and Michael Cline, DO
- Poster Number: P3339
- Session Time: Monday, October 28, 10:30 a.m. – 4:15 p.m. ET
- Presenting Author: David Kunkel, MD
Attendees will be able to explore pivotal research on GIMOTI and its relevance in the treatment of GI disorders.
Expanded Presence at ACG
In addition to the compelling presentations, Evoke Pharma will have a newly expanded exhibit booth, showcasing their latest marketing campaign for GIMOTI. The booth will be located at position #361 in the ACG Exhibit Hall. Attendees are encouraged to stop by and engage with Evoke's management and commercial teams to learn more about GIMOTI and its benefits.
About GIMOTI and Diabetic Gastroparesis
GIMOTI is a groundbreaking treatment designed for adults suffering from acute and recurrent diabetic gastroparesis, a disease that significantly affects the stomach's function, causing it to empty contents too slowly. This condition can lead to severe symptoms and complications, including the improper absorption of orally administered medications. Before the advent of GIMOTI, metoclopramide was only available in oral and injectable forms. The nasal spray formulation is now the only FDA-approved drug in the United States specifically indicated for treating this challenging condition.
Learn More and Stay Connected
To gather further information about Evoke Pharma and their innovative research, visit their website at www.EvokePharma.com. The company is also active on social media, connecting with audiences on platforms like LinkedIn and Twitter. Follow them to stay updated on their latest news and developments.
Investor & Media Contact Information
For inquiries, please reach out to:
Daniel Kontoh-Boateng
DKB Partners
Tel: 862-213-1398
Email: dboateng@dkbpartners.net
Frequently Asked Questions
What is Evoke Pharma known for?
Evoke Pharma specializes in developing treatments for gastrointestinal disorders, particularly focusing on their innovative nasal spray formulation, GIMOTI.
What is GIMOTI used to treat?
GIMOTI is used to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults, helping to relieve gastrointestinal discomfort.
Which awards has Evoke Pharma recently received?
The company received the Outstanding Research Award and the Presidential Poster Award for their abstract at the ACG Annual Scientific Meeting.
When is the ACG Annual Scientific Meeting taking place?
The ACG Annual Scientific Meeting will be held from October 25-29, 2024, in Philadelphia.
How can I learn more about Evoke Pharma?
You can visit their official website at www.EvokePharma.com or follow them on social media for updates and information.
